Skip to main content
HCPCS J9263 · Level II · Part B drug

J9263: oxaliplatin, HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J9263

Billing unit
0.5 MG
Oxaliplatin
ASP payment limit
$0.087
October 2026; +58.2% vs July 2026
Practitioner MUE
700
MAI 3
OPPS status
SI N
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9263 is the Level II code for Injection, oxaliplatin, 0.5 mg, billed per 0.5 MG. The Medicare Part B ASP payment limit for October 2026 is $0.087 per billing unit, up 58.2% from July 2026. The practitioner MUE allows up to 700 units per date of service (MAI 3), so a full 700-unit day is $60.90 at the current limit. Under OPPS it carries status indicator N. J9263 is billed in units of 0.5 MG; the quantity administered, the NDC package and the units on the claim must reconcile, which is the check that prevents CARC 16 and 151 returns on this line. The ASP crosswalk maps 40 NDCs to it, sold as Oxaliplatin by Teva Parenteral Medicines, Inc., Sandoz Inc., Accord Healthcare Inc. No current Billing and Coding Article lists J9263, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9263 at $0.087 per 0.5 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $0.055 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9263
QuarterPayment limitPerCoinsurance
October 2026$0.0870.5 MG20%
July 2026$0.0550.5 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 40 NDCs from 14 labelers to J9263. Report the NDC in the claim's drug segment and bill the number of J9263 units that equals the quantity administered divided by 0.5 MG; the last column gives units per full package.

NDCs that crosswalk to J9263
NDCDrug nameLabelerPackage sizeBilling units / package
00703-3985-01OxaliplatinTeva Parenteral Medicines, Inc.10 × 1100
00703-3986-01OxaliplatinTeva Parenteral Medicines, Inc.20 × 1200
00781-3315-70OxaliplatinSandoz Inc.10 × 1100
00781-3317-80OxaliplatinSandoz Inc.20 × 1200
00781-9315-70OxaliplatinSandoz Inc.10 × 1100
00781-9317-80OxaliplatinSandoz Inc.20 × 1200
16729-0332-03OxaliplatinAccord Healthcare Inc10 × 1100
16729-0332-05OxaliplatinAccord Healthcare Inc20 × 1200
25021-0233-10OxaliplatinSagent Pharmaceuticals10 × 1100
25021-0233-20OxaliplatinSagent Pharmaceuticals20 × 1200
50742-0405-10OxaliplatinIngenus Pharmaceuticals LLC10 × 1100
55150-0331-01OxaliplatinEugia US LLC10 × 1100
55150-0332-01OxaliplatinEugia US LLC20 × 1200
60505-6132-06OxaliplatinApotex Corp10 × 1100
60505-6132-07OxaliplatinApotex Corp20 × 1200
60505-6132-08OxaliplatinApotex Corp40 × 1400
60505-6287-02OxaliplatinApotex Corp10 × 1100
60505-6287-04OxaliplatinApotex Corp20 × 1200
61703-0363-18OxaliplatinPfizer Inc10 × 1100
61703-0363-22OxaliplatinPfizer Inc20 × 1200
63323-0750-10OxaliplatinFreseniUS Kabi USA, LLC10 × 1100
63323-0750-20OxaliplatinFreseniUS Kabi USA, LLC20 × 1200
67457-0442-20OxaliplatinMylan Institutional LLC20 × 1200
67457-0469-10OxaliplatinMylan Institutional LLC10 × 1100
68001-0468-36OxaliplatinBluePoint Laboratories10 × 1100
68001-0468-37OxaliplatinBluePoint Laboratories20 × 1200
71288-0101-10OxaliplatinMeitheal Pharmaceuticals Inc.10 × 1100
71288-0101-20OxaliplatinMeitheal Pharmaceuticals Inc.20 × 1200
71288-0149-95OxaliplatinMeitheal Pharmaceuticals Inc.10 × 1100
71288-0149-96OxaliplatinMeitheal Pharmaceuticals Inc.20 × 1200
71288-0171-11OxaliplatinMeitheal Pharmaceuticals Inc.10 × 1100
71288-0171-91OxaliplatinMeitheal Pharmaceuticals Inc.10 × 1100
71288-0172-21OxaliplatinMeitheal Pharmaceuticals Inc.20 × 1200
71288-0172-92OxaliplatinMeitheal Pharmaceuticals Inc.20 × 1200
72266-0161-01OxaliplatinFosun Pharma USA Inc.10 × 1100
72266-0162-01OxaliplatinFosun Pharma USA Inc.20 × 1200
72603-0101-01OxaliplatinNorthstar RxLLC20 × 1200
72603-0301-01OxaliplatinNorthstar RxLLC10 × 1100
72603-0320-01OxaliplatinNorthstar RxLLC20 × 1200
72603-0420-01OxaliplatinNorthstar RxLLC10 × 1100

Medically Unlikely Edits (MUE)

CMS publishes 3 MUE values for J9263. For practitioners the limit is 700 units per date of service with adjudication indicator 3, a date-of-service clinical edit: units above the limit deny but can be paid on appeal with documentation that the quantity was medically reasonable.

MUE values for J9263 by setting
SettingMUE (units/DOS)MAICMS rationale
Practitioner services7003 Date of Service Edit: ClinicalClinical: Data
Facility outpatient hospital7003 Date of Service Edit: ClinicalClinical: Data
DME supplier03 Date of Service Edit: ClinicalCMS Policy

MUE for J9263 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9263 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J9263 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J9263 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9263 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J9263 carries status indicator N. Status N means payment is packaged into the associated procedure and no separate OPPS payment is made.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J9263 carries payment indicator N1, which CMS defines as "Packaged service/item; no separate payment made". An N1 drug is packaged in the ASC: the facility receives no separate payment because the surgical procedure's rate already includes it.

Common denials for J9263 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J9263

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J9263

What does HCPCS code J9263 describe?

J9263 is defined by CMS as "Injection, oxaliplatin, 0.5 mg". Each billing unit represents 0.5 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J9263 a CPT code?

No. J9263 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as oxaliplatin; CPT codes are five-character codes maintained by the AMA. On a Part B claim J9263 reports the drug itself in 0.5 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J9263 in October 2026?

The ASP-based payment limit is $0.087 per 0.5 MG, with 20% beneficiary coinsurance. The July 2026 limit was $0.055. Commercial payers use their own fee schedules.

How many units of J9263 can be billed per day?

The practitioner Medically Unlikely Edit is 700 units per date of service with adjudication indicator 3 (Date of Service Edit: Clinical). MAI 3 edits can be appealed with documentation that the units were medically reasonable. CMS cites "Clinical: Data" as the rationale.

Which NDCs map to J9263?

The October 2026 ASP crosswalk lists 40 NDCs from 14 labelers: Oxaliplatin (Teva Parenteral Medicines, Inc.); Oxaliplatin (Sandoz Inc.); Oxaliplatin (Accord Healthcare Inc); Oxaliplatin (Sagent Pharmaceuticals). For example NDC 00703-3985-01 (package size 10) equals 100 billing units of J9263.

Does J9263 have NCCI bundling edits?

No active practitioner PTP pairs list J9263 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.